Trial Profile
A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Licogliflozin (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 Mar 2020 Primary endpoint has been met. (Percent Change From Baseline in Body Weight at 24 Weeks)
- 18 Mar 2020 Results published in the Obesity (Silver Spring, Md.)
- 01 Oct 2018 Status changed from active, no longer recruiting to completed.